Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

GILD AMGN BIIB CELG 
Benchmark  United States  NYSE  10,980   70.83 Index Moved Up 0.65%  


Processing
Collecting data for STEM

StemCells Inc

   
$1.38
Change0.00No Change0.00%
Year To Date
1.152.43
Last 1 Month(s)
1.381.59
5 Days Price Trend
September 17, 2014 
Highest Price  
Lowest Price  
August 18, 2014 
September 16, 2014 

StemCells Market Sensitivity

As returns on market increase, StemCells returns are expected to increase less than the market. However during bear market, the loss on holding StemCells will be expected to be smaller as well.
StemCells Inc Small BetaStemCells Inc Beta Legend
STEM
StemCells Inc
USA Stock
Healthcare
Biotechnology
Benchmark NYSE
http://www.stemcellsinc.com
Contact Number: 510. 456. 4000
Currency: USD - US Dollar
Traded on Nasdaq Capital Markets
 
Current Valuation102.85 M
Shares Outstanding68.64 M
Number of Shares Shorted1.81 M
Revenue1.22 M
 United States Nasdaq   0.75 % Macroaxis: 0.75 Moved Up  
 
 United States SP 500   0.75 % Macroaxis: 0.75 Moved Up  
 
 United States NYSE   0.65 % Macroaxis: 0.65 Moved Up  
 
 United States Russel   0.39 % Macroaxis: 0.39 Moved Up  
 
 thisGreen STEM STEM agains markets  0.00 % No Change  
Compare to Competition   Compare Correlations

StemCells Leadership

Martin McGlynn CEO and President Director, Member of Strategic Transactions Committee, CEO of StemCells California Inc and President of StemCells California Inc
John Schwartz Independent Chairman of the Board, Ph.D
Gregory Schiffman CFO, Executive Vice President - Finance, MBA
CPA MBA CFO and Executive VP of Fin.

StemCells Diversification Suggestion

Use StemCells to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment . Check odds of StemCells to be traded at $1.3662 in 30 days

StemCells Price and Market Media

The median price of StemCells for the period between Mon, Aug 18, 2014 and Wed, Sep 17, 2014 is 1.54 with a coefficient of variation of 4.18. The daily time series for the period is distributed with a sample standard deviation of 0.06, arithmetic mean of 1.5, and mean deviation of 0.05. The Stock received some media coverage during the period.
StemCells Value
 
Change Benchmark  Embed   Timeline 

StemCells Summary

StemCells Inc [STEM] is traded on Nasdaq Capital Markets in USA. It is located in Newark, CA and employs 58 people. The company currently falls under 'Small-Cap' category with current market capitalization of 105.7 M. StemCells Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 68.64 M outstanding shares of which 1.81 M shares are at this time shorted by private and institutional investors with about 3.5 trading days to cover.
StemCells, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for stem cellbased research and drug discovery and development. more
Over 30
Days
0
Out Of
100
 
More
Than
95
%
 
Hyped down

StemCells Alerts

StemCells Inc generates negative expected return over the last 30 days
StemCells Inc may become a speculative penny stock
StemCells Inc has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 1.22 M. Net Loss for the year was (33.89 M) with profit before overhead, payroll, taxes, and interest of 886.64 K.
STEMCELLS INC currently holds about 17.85 M in cash with (27.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.26.
Trending Tickers YPF S.A. Twitter StemCells Inc ...

StemCells Research Report

  
Generate Report  

StemCells Pair Trading Analysis

Correlation analysis and pair trading evaluation for StemCells and Gilead Sciences
  

Explore Investment Opportunities

Investing ideals could easily outperform a given market if properly optimized

StemCells Executives

CPA MBA CFO and Executive VP of Fin.

StemCells Directors

Irving Weissman Director
Eric Bjerkholt Independent Director
R Greer Independent Director
Ricardo Levy Independent Director
Alan Trounson Director

StemCells Management

Ann Tsukamoto Executive VP of Scientific and Strategic Alliances
George Koshy Chief Accounting Officer and Controller
Kenneth Stratton General Counsel

StemCells Fundamentals

EBITDA vs Current Valuation
Z Score vs Debt to Equity
EBITDA vs One Year High
Total Asset vs Debt to Equity

StemCells vs Competition

StemCells vs. Gilead Sciences Inc
StemCells vs. Amgen Inc
StemCells vs. Biogen Idec Inc
StemCells vs. Celgene Corporation
StemCells vs. Regeneron Pharmaceuticals Inc
StemCells vs. Alexion Pharmaceuticals Inc
StemCells vs. Illumina Inc
StemCells vs. Vertex Pharmaceuticals Incorporated
StemCells vs. BioMarin Pharmaceutical Inc
StemCells vs. Jazz Pharmaceuticals Public Limited Company

StemCells September 17, 2014 Opportunity Range

Information Ratio(0.32)
Maximum Drawdown5.83
Value At Risk(3.14)
Potential Upside1.95

 

Analytics

Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 

Research Modules

Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 

Services And Technology

Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 

Free Investor Tools

World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 

About Us

About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities